CD38/CD31 Interactions Activate Genetic Pathways Leading to Proliferation and Migration in Chronic Lymphocytic Leukemia Cells

Overview

Journal Mol Med

Publisher Biomed Central

Specialties General Medicine
Molecular Biology

Date 2009 Dec 4

PMID 19956559

Citations 38

Authors

Silvia Deaglio

Semra Aydin

Maurizia Mello Grand

Tiziana Vaisitti

Luciana Bergui

Giovanni DArena

Giovanna Chiorino

Fabio Malavasi

Affiliations

Soon will be listed here.

Abstract

Human CD38 is a pleiotropic glycoprotein belonging to a family of enzymes/receptors involved in the catabolism of extracellular nucleotides. CD38-receptor activities are regulated through binding to the nonsubstrate ligand CD31. CD38 expression above a critical threshold is a negative prognostic marker for chronic lymphocytic leukemia (CLL) patients. Activation of CD38 by means of agonistic monoclonal antibodies or the CD31 ligand induces proliferation and immunoblast differentiation of CLL cells. Here we define the genetic signature that follows long-term in vitro interactions between CD38(+) CLL lymphocytes and CD31(+) cells. The emerging profile confirms that the CD31/CD38 axis activates genetic programs relevant for proliferative responses. It also indicates a contribution of this pathway to the processes mediating migration and homing. These results further support the notion that the CD31/CD38 axis is part of a network of accessory signals that modify the microenvironment, favoring localization of leukemic cells to growth-permissive sites.

Citing Articles

Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Visal T, Bayraktar R, den Hollander P, Attathikhun M, Zhou T, Wang J Cancer Res. 2025; 85(5):894-911.

PMID: 39853244 PMC: 11873730. DOI: 10.1158/0008-5472.CAN-24-0400.

Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy.

Song S, Gan J, Long Q, Gao Z, Zheng Y Vaccines (Basel). 2025; 13(1).

PMID: 39852780 PMC: 11768799. DOI: 10.3390/vaccines13010001.

Functional identification of soluble uric acid as an endogenous inhibitor of CD38.

Wen S, Arakawa H, Yokoyama S, Shirasaka Y, Higashida H, Tamai I Elife. 2024; 13.

PMID: 39527634 PMC: 11554305. DOI: 10.7554/eLife.96962.

Biological Functions and Therapeutic Potential of NAD Metabolism in Gynecological Cancers.

Myong S, Nguyen A, Challa S Cancers (Basel). 2024; 16(17).

PMID: 39272943 PMC: 11394644. DOI: 10.3390/cancers16173085.

Development of New CD38 Targeted Peptides for Cancer Imaging.

Zheleznyak A, Tang R, Duncan K, Manion B, Liang K, Xu B Mol Imaging Biol. 2024; 26(4):738-752.

PMID: 38480650 PMC: 11282151. DOI: 10.1007/s11307-024-01901-5.

References

Patten P, Buggins A, Richards J, Wotherspoon A, Salisbury J, Mufti G . CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008; 111(10):5173-81. DOI: 10.1182/blood-2007-08-108605. View

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F . In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood. 2006; 108(4):1135-44. DOI: 10.1182/blood-2006-01-013003. View

Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein A, Ortolan E . Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88(3):841-86. DOI: 10.1152/physrev.00035.2007. View

Shanafelt T, Kay N . The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol. 2006; 33(2):174-85. DOI: 10.1053/j.seminoncol.2006.01.008. View

Pepper C, WARD R, Lin T, Brennan P, Starczynski J, Musson M . Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia. 2007; 21(4):687-96. DOI: 10.1038/sj.leu.2404587. View

Deaglio S, Vaisitti T, Aydin S, Bergui L, DArena G, Bonello L . CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007; 110(12):4012-21. DOI: 10.1182/blood-2007-06-094029. View

Deaglio S, Morra M, Mallone R, Ausiello C, Prager E, Garbarino G . Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998; 160(1):395-402. View

Matrai Z . CD38 as a prognostic marker in CLL. Hematology. 2005; 10(1):39-46. DOI: 10.1080/10245330400020470. View

10.

Damle R, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C . CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007; 110(9):3352-9. PMC: 2200908. DOI: 10.1182/blood-2007-04-083832. View

11.

Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M . ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75. DOI: 10.1056/NEJMoa023143. View

12.

Tomfohr J, Lu J, Kepler T . Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics. 2005; 6:225. PMC: 1261155. DOI: 10.1186/1471-2105-6-225. View

13.

Tonino S, Spijker R, Luijks D, van Oers M, Kater A . No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood. 2008; 112(3):840-3. DOI: 10.1182/blood-2008-03-144576. View

14.

Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A . Role of angiogenesis in chronic lymphocytic leukemia. Cancer. 2006; 107(5):925-34. DOI: 10.1002/cncr.22086. View

15.

Deaglio S, Vaisitti T, Billington R, Bergui L, Omede P, Genazzani A . CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood. 2007; 109(12):5390-8. DOI: 10.1182/blood-2006-12-061812. View

16.

Lin T, Hewamana S, Ward R, Taylor H, Payne T, Pratt G . Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient. Br J Haematol. 2008; 142(4):595-605. DOI: 10.1111/j.1365-2141.2008.07236.x. View

17.

Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U . CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003; 102(6):2146-55. DOI: 10.1182/blood-2003-03-0989. View

18.

Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U . CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol. 2000; 75:99-120. View

19.

Jaksic O, Kardum Paro M, Kardum Skelin I, Kusec R, Pejsa V, Jaksic B . CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood. 2004; 103(5):1968-9. DOI: 10.1182/blood-2003-11-3890. View

20.

Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein A, Tamagnone L . CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood. 2004; 105(8):3042-50. DOI: 10.1182/blood-2004-10-3873. View